Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc. (INM)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: InMed is a clinical-stage pharmaceutical company developing proprietary small molecule drug candidates targeting diseases with high unmet medical needs (Alzheimer's, dry AMD, Epidermolysis Bullosa). It operates two segments: InMed Pharma (R&D) and BayMedica Commercial (manufacturing and sale of bulk rare cannabinoids for the health and wellness sector).
Listing Status: The Company is listed on Nasdaq. On November 14, 2024, it effected a 20-for-1 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.
Key Financial Metrics
| Metric (USD) | Q1 2024 (3 Months Ended Sept 30) | Q1 2023 (3 Months Ended Sept 30) |
|---|---|---|
| Revenue | $1,264,638 | $901,862 |
| Gross Profit | $493,413 | $21,242 |
| Gross Margin | 39.0% | 2.4% |
| Net Loss | $(1,677,868) | $(2,536,828) |
| Net Loss Per Share (Basic/Diluted) | $(2.71) | $(15.24) |
| Cash and Cash Equivalents | $5,583,039 | $6,738,304 |
| Total Assets | $10,465,106 | $11,822,782 |
| Total Liabilities | $2,069,662 | $2,616,673 |
| Accumulated Deficit | $(110,753,627) | $(103,937,037) |
Cash Flow Summary (Q1 2024):
- Cash used in operating activities: $(1,826,810)
- Cash provided by financing activities: $838,239 (primarily from ATM private placement)
- Net decrease in cash: $(988,571)
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 40% to $1.26 million, driven entirely by the BayMedica Commercial segment due to expanded marketing and increased demand for rare cannabinoids.
- Margin Expansion: Gross profit surged to $493,413 (39% margin) from $21,242 (2.4% margin). This improvement was primarily due to a significant reduction in inventory write-downs compared to the prior year.
- Reduced Net Loss: Net loss decreased by approximately $859,000 (34%) compared to the prior year, reflecting higher gross profits and reduced R&D expenses in the InMed Pharma segment.
- R&D Expenses: InMed Pharma R&D expenses decreased 40% to $763,000, attributed to lower external contractor costs and patent fees, partially offset by increased research supplies.
- Financing Activity: The Company raised approximately $1.03 million in gross proceeds via its At-The-Market (ATM) program during the quarter, net of $192,000 in issuance costs.
Outlook, Risks, and Contingencies
Going Concern: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for one year from the issuance date. Cash on hand ($5.6 million) is projected to fund operations only through the end of Q1 2025. Future viability depends on raising additional capital.
Guidance and Outlook:
- Capital Needs: The Company expects to incur substantial operating losses and negative cash flows for the foreseeable future as it advances clinical trials and manufacturing technologies.
- Listing Compliance: The Company executed a 20-for-1 reverse stock split on November 14, 2024, to meet Nasdaq's $1.00 minimum bid price rule. Continued listing is contingent on maintaining this price for ten consecutive trading days by December 2, 2024.
- Product Pipeline: Positive preclinical data was announced for INM-901 (Alzheimer's) and INM-755 (Epidermolysis Bullosa). The Company is seeking strategic partnerships for commercialization.
Risks and Contingencies:
- Delisting Risk: Failure to maintain the minimum bid price post-split could result in delisting, severely impacting liquidity and financing ability.
- Legal Proceedings: BayMedica is in a dispute with a third-party licensor regarding royalty payments under a Patent License Agreement. The licensor has alleged breach of contract; the Company disputes the claim and intends to defend vigorously. No lawsuit has been filed as of the filing date.
- Customer Concentration: Revenue is concentrated among a few customers. In Q1 2024, four customers accounted for 75% of total revenue.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.6 million cash balance to fund operations through Q1 2025 and the timeline for the next capital raise.
- Nasdaq Compliance: Monitor the stock price post-split to ensure it remains above $1.00 for the required ten consecutive trading days to avoid delisting.
- Legal Dispute: Track the status of the BayMedica patent license dispute and potential arbitration outcomes.
- Revenue Sustainability: Assess the durability of BayMedica's revenue growth and the impact of customer concentration on future cash flows.
- Dilution Impact: Review the terms of the ATM program and the impact of the reverse stock split on share count and potential future dilution.